Similarly, clinical and endoscopic outcomes were achieved with risankizumab 1200 mg across AT-IR subgroups categorized by AT mechanism of action (TNF inhibitor, vedolizumab, JAK inhibitor) or specific TNF inhibitor type (infliximab, adalimumab, golimumab); these subgroups were not mutually exclusive (Figures 1 and S2). This evidence concerns the gene TNF and ataxia telangiectasia.